Show simple item record

dc.contributor.authorEriksson, Mia D.
dc.contributor.authorEriksson, Johan G.
dc.contributor.authorKautiainen, Hannu
dc.contributor.authorSalonen, Minna K.
dc.contributor.authorMikkola, Tuija M.
dc.contributor.authorKajantie, Eero
dc.contributor.authorWasenius, Niko
dc.contributor.authorvon Bonsdorff, Mikaela
dc.contributor.authorLaine, Merja K.
dc.date.accessioned2021-05-06T10:48:06Z
dc.date.available2021-05-06T10:48:06Z
dc.date.issued2021
dc.identifier.citationEriksson, M. D., Eriksson, J. G., Kautiainen, H., Salonen, M. K., Mikkola, T. M., Kajantie, E., Wasenius, N., von Bonsdorff, M., & Laine, M. K. (2021). Advanced glycation end products measured by skin autofluorescence are associated with melancholic depressive symptoms : Findings from Helsinki birth cohort study. <i>Journal of Psychosomatic Research</i>, <i>145</i>, Article 110488. <a href="https://doi.org/10.1016/j.jpsychores.2021.110488" target="_blank">https://doi.org/10.1016/j.jpsychores.2021.110488</a>
dc.identifier.otherCONVID_66410308
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/75347
dc.description.abstractBackground Millions of people live with depression and its burden of disease. Depression has an increased comorbidity and mortality that has remained unexplained. Studies have reported connections between advanced glycation end products (AGEs) and various disease processes, including mental health. The present study evaluated associations between AGEs, depressive symptoms, and types of depressive symptoms. Methods From the Helsinki Birth Cohort Study, 815 participants with a mean age of 76 years were recruited for this cross-sectional study. Characteristics regarding self-reported lifestyle and medical history, as well as blood tests were obtained along with responses regarding depressive symptoms according to the Beck Depression Inventory (BDI) and Mental Health Inventory-5. Each participant had their AGE level measured non-invasively with skin autofluorescence (SAF). Statistical analyses looked at relationships between types of depressive symptoms and AGE levels by sex. Results Of women, 27% scored ≥10 on the BDI and 18% of men, respectively. Men had higher crude AGE levels (mean [standard deviation], arbitrary units) (2.49 [0.51]) compared to women (2.33 [0.46]) (p < 0.001). The highest crude AGE levels were found in those with melancholic depressive symptoms (2.61 [0.57]), followed by those with non-melancholic depressive symptoms (2.45 [0.45]) and those with no depressive symptoms (2.38 [0.49]) (p = 0.013). These findings remained significant in the fully adjusted model. Conclusions The current study shows an association between depressive symptoms and higher AGE levels. The association is likely part of a multi-factorial effect, and hence no directionality, causality, or effect can be inferred solely based on the results of this study.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJournal of Psychosomatic Research
dc.rightsCC BY 4.0
dc.subject.otheradvanced glycation end products
dc.subject.otherbiomarkers
dc.subject.othercohort studies
dc.subject.othercomorbidity
dc.subject.otherdepression
dc.subject.otherdepressive disorder
dc.subject.otherinflammation
dc.titleAdvanced glycation end products measured by skin autofluorescence are associated with melancholic depressive symptoms : Findings from Helsinki birth cohort study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202105062646
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineGerontologia ja kansanterveysfi
dc.contributor.oppiaineGerontology and Public Healthen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.description.reviewstatuspeerReviewed
dc.relation.issn0022-3999
dc.relation.volume145
dc.type.versionpublishedVersion
dc.rights.copyright© 2021 The Author(s). Published by Elsevier Inc.
dc.rights.accesslevelopenAccessfi
dc.subject.ysobiomarkkerit
dc.subject.ysotulehdus
dc.subject.ysomasennus
dc.subject.ysoikääntyneet
dc.subject.ysokohorttitutkimus
dc.subject.ysoaineenvaihduntatuotteet
dc.subject.ysokomorbiditeetti
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p12288
jyx.subject.urihttp://www.yso.fi/onto/yso/p1049
jyx.subject.urihttp://www.yso.fi/onto/yso/p7995
jyx.subject.urihttp://www.yso.fi/onto/yso/p2433
jyx.subject.urihttp://www.yso.fi/onto/yso/p25606
jyx.subject.urihttp://www.yso.fi/onto/yso/p24583
jyx.subject.urihttp://www.yso.fi/onto/yso/p18495
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1016/j.jpsychores.2021.110488
jyx.fundinginformationThe HBCS has been supported by grants from Finska Läkaresällskapet, the Finnish Special Governmental Subsidy for Health Sciences, Academy of Finland (126775, 127437, 129255, 129306, 129907, 130326, 134791, 209072, 210595, 213225, 263924, 275074 and 315690), Samfundet Folkhälsan, Liv och Hälsa, EU FP7 [Developmental Origins of Healthy Aging (DORIAN)] project number 278603, and EU H2020-PHC-2014-DynaHealth grant 633595 and EU Horizon 2020 Award 733206 LIFECYCLE (all for the Helsinki Birth Cohort Study), European Commission, Horizon2020 award 733280 RECAP), Foundation for Cardiovascular Research, Foundation for Diabetes Research, Foundation for Pediatric Research, Novo Nordisk Foundation, Signe and Ane Gyllenberg Foundation.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0